<DOC>
	<DOCNO>NCT00490360</DOCNO>
	<brief_summary>Neodajuvant chemotherapy gemcitabine / cisplatin apply patient resectable cancer pancreatic head .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Resectable Cancer Pancreatic Head</brief_title>
	<detailed_description>Neodajuvant chemotherapy gemcitabine / cisplatin apply patient resectable cancer pancreatic head . Two cycle chemotherapy give day 1 15 . After restaging excludes disease progression , standard Whipple procedure perform . Staging restaging procedure include abdominal CT , diagnostic laparoscopy , PET/CT , tumor marker ( CEA , CA 19-9 ) assessment quality life QLQ-30 . - Trial medicinal product</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Age &gt; 18 year Histologically cytologically confirm resectable ductal adenocarcinoma pancreatic head WHOperformance status 02 Written informed consent Discussion intrdisciplinary conference Exclusion criterion : Insufficient renal function ( calculate creatinin clearance &lt; 60ml ( min ) Insufficient hematologic function ( neutrophil count &lt; 1'000/ul , platelet &lt; 100'000/ul ) Uncorrectable coagulopathy Severe cholestasis ( bilirubin &gt; 100mmol/l ) Distant metastases liver , lung organ Peritoneal carcinomatosis Unresectable tumor ( . 4.2 . ) Contraindication Whipple procedure Uncontrolled infection Neurotphil count &gt; Â°2 Estimated life experience &lt; 6 month HIV Infection Severe medical psychatric comorbidities interefere participation trial inform consent Female patient childbearing age without adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>